Therapeutic Lowering of Lipoprotein(a) A Role for Pharmacogenetics?

被引：9
作者：
Boffa, Michael B. [2 ]
Koschinsky, Marlys L. [1 ]
机构：
[1] Univ Western Ontario, Robarts Res Inst, Schulich Sch Med & Dent, Room 2260,1151 Richmond St N, London, ON N6A 5B7, Canada
[2] Univ Western Ontario, Dept Biochem, Schulich Sch Med & Dent, London, ON, Canada
来源：
CIRCULATION-GENOMIC AND PRECISION MEDICINE | 2018年 / 11卷 / 02期
基金：
加拿大自然科学与工程研究理事会; 加拿大健康研究院;
关键词：
Editorials; cardiovascular diseases; genetics; lipoprotein(a); naicin; pharmacogenetics; risk factors; EXTENDED-RELEASE NIACIN; SERIES LIPOPROTEIN; ISOFORM SIZE; APOLIPOPROTEIN(A); LP(A); RISK; DISEASE; IMPACT; AGE;
D O I：
10.1161/CIRCGEN.118.002052
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 20 条
[1]   Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes The AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglyceride and Impact on Global Health Outcomes) [J].
Albers, John J. ;
Slee, April ;
O'Brien, Kevin D. ;
Robinson, Jennifer G. ;
Kashyap, Moti L. ;
Kwiterovich, Peter O., Jr. ;
Xu, Ping ;
Marcovina, Santica M. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 62 (17) :1575-1579
[2]   Identification of sequences in apolipoprotein(a) that maintain its closed conformation: A novel role for apo(a) isoform size in determining the efficiency of covalent Lp(a) formation [J].
Becker, L ;
Cook, PM ;
Koschinsky, ML .
BIOCHEMISTRY, 2004, 43 (31) :9978-9988
[3]   Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy [J].
Boden, William E. ;
Probstfield, Jeffrey L. ;
Anderson, Todd ;
Chaitman, Bernard R. ;
Desvignes-Nickens, Patrice ;
Koprowicz, Kent ;
McBride, Ruth ;
Teo, Koon ;
Weintraub, William .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (24) :2255-2267
[4]   Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice [J].
Chennamsetty, Indumathi ;
Kostner, Karam M. ;
Claudel, Thierry ;
Vinod, Manjula ;
Frank, Sasa ;
Weiss, Thomas S. ;
Trauner, Michael ;
Kostner, Gerhard M. .
JOURNAL OF LIPID RESEARCH, 2012, 53 (11) :2405-2412
[5]   The renaissance of lipoprotein(a): Brave new world for preventive cardiology? [J].
Ellis, Katrina L. ;
Boffa, Michael B. ;
Sahebkar, Amirhossein ;
Koschinsky, Marlys L. ;
Watts, Gerald F. .
PROGRESS IN LIPID RESEARCH, 2017, 68 :57-82
[6]   Lipoprotein (a): impact by ethnicity and environmental and medical conditions [J].
Enkhmaa, Byambaa ;
Anuurad, Erdembileg ;
Berglund, Lars .
JOURNAL OF LIPID RESEARCH, 2016, 57 (07) :1111-1125
[7]   Apolipoprotein(a) Isoforms and the Risk of Vascular Disease Systematic Review of 40 Studies Involving 58,000 Participants [J].
Erqou, Sebhat ;
Thompson, Alexander ;
Di Angelantonio, Emanuele ;
Saleheen, Danish ;
Kaptoge, Stephen ;
Marcovina, Santica ;
Danesh, John .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (19) :2160-2167
[8]   Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans [J].
Graham, Mark J. ;
Viney, Nick ;
Crooke, Rosanne M. ;
Tsimikas, Sotirios .
JOURNAL OF LIPID RESEARCH, 2016, 57 (03) :340-351
[9]   Lipoprotein(a): resurrected by genetics [J].
Kronenberg, F. ;
Utermann, G. .
JOURNAL OF INTERNAL MEDICINE, 2013, 273 (01) :6-30
[10]   Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients [J].
Landray, Martin J. ;
Haynes, Richard ;
Hopewell, Jemma C. ;
Parish, Sarah ;
Aung, Theingi ;
Tomson, Joseph ;
Wallendszus, Karl ;
Craig, Martin ;
Jiang, Lixin ;
Collins, Rory ;
Armitage, Jane .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (03) :203-212
12